CinCor Archives - Medical Design Sourcing

The next wave: 10 promising investigational antihypertensive drugs to watch

[Image courtesy of Adobe Stock]

Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide. This review highlights ten promising antihypertensive drug candidates with the potential to address pulmonary arterial hypertension (PAH), resistant hypertension and uncontrolled hypertension.

Aprocitentan, developed by Janssen NYSE:JNJ) and Idorsia (SIX:IDIA), is an experimental oral drug designed to treat resistant hypertension. As a dual endothelin receptor antagonist (ERA), it effectively blocks the binding of ET-1 to both ET A and ET B receptors. The drug has a low likelihood of interacting with other medications and its mechanism of action is well-suited for treating resistant hypertension. In clinical trials, aprocitentan demonstrated better blood pressure reduction than placebo, with the effects lasting up to week 40, and was generally well-tolerated by patients. (Text continues beneath th…

CinCor stock surges after AstraZeneca announces plan to buy company for up to $1.8B

AstraZeneca (LON:AZN) announced it had reached an agreement to acquire CinCor Pharma (Nasdaq:CINC). After announcing the proposed deal, CinCor’s share price jumped 144% to $28.74.

AstraZeneca has agreed to a tender offer to acquire outstanding shares of CinCor for $26 per share, or $1.3 billion.

CinCor specializes in developing therapies for hypertension and chronic kidney disease.

In an interview with Drug Discovery & Development in December, CinCor Chief Operating Officer Catherine Pearce explained why it was confident that its drug candidate, baxdrostat, could address a large unmet medical need in treatment-resistant hypertension.

AstraZeneca said the acquisition would bolster its cardiorenal pipeline.

The company said it would offer CinCor an additional $10 per share after a specified regulatory filing related to baxdrostat.

AstraZeneca also agreed to acquire the cash and marketable securities on CinCor’s balance sheet for ro…

CinCor’s COO has a mission to transform hypertension treatment

The clinical-stage biopharma CinCor is developing baxdrostat, a highly selective, oral small molecule inhibitor of aldosterone synthase, for hypertension.

Catherine Pearce, chief operating officer and co-founder of CinCor, acknowledges that the company has received criticism for its plan to bring a new drug into the highly genericized blood pressure control market. “The reality is that cardiovascular disease is still the number one killer, and we’re woefully behind in treating patients to their optimal goals,” Pearce said.

Although many generic hypertension medicines exist, the current treatment landscape is less than ideal. “Sometimes patients feel worse taking medications. Or they’re not taking enough of the medication, and they’re still having a hard time getting to target,” Pearce said. Millions of people have treatment-resistant hypertension.

The complexity of heart disease is not the most challenging aspect…